CF
GYRE icon

Corebridge Financial’s Gyre Therapeutics GYRE Stock Holding History

Corebridge Financial’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,417
Closed -$26.4K – 1169
2025
Q1 		$26.4K Sell
3,417
-51
-1% -$559 ﹤0.01% 2862
2024
Q4 		$42K Sell
3,468
-262
-7% -$3.35K ﹤0.01% 2867
2024
Q3 		$46.8K Sell
3,730
-22
-0.6% -$284 ﹤0.01% 2876
2024
Q2 		$44.8K Buy
+3,752
New +$51.5K ﹤0.01% 2916

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Corebridge Financial's GYRE Position: Q2 2025 in Review

Corebridge Financial sold out of Gyre Therapeutics (GYRE) in Q2 2025, closing a stake of 3,417 shares — an estimated $26.4K sold.

Corebridge Financial first reported a position in GYRE in Q2 2024 and held it in 4 quarters. The position peaked at $46.8K in Q3 2024. 48 funds tracked by Wall St. Rank hold GYRE as of Q2 2025.

  • Corebridge Financial reported no remaining Gyre Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 3,417 Gyre Therapeutics shares in Q2 2025, an estimated $26.4K.
  • Corebridge Financial first reported a position in Gyre Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Gyre Therapeutics position peaked at $46.8K in Q3 2024.
  • 48 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.